Ionis Pharmaceuticals (IONS) PT Lowered to $85 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Price: $44.27 -2.49%
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Barclays analyst Eliana Merle lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $85.00 (from $90.00) while maintaining a Overweight rating.
You May Also Be Interested In
- BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform
- FDA approves GSK's Hibsago for chronic hepatitis B treatment
- Pegasystems (PEGA) PT Lowered to $43 at Rosenblatt
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
